Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cloprostenol isopropyl ester is a synthetic small molecule analog of prostaglandin F2α (PGF2α) and a potent agonist of the FP (prostaglandin F) receptor. As a more lipid-soluble isopropyl ester prodrug of the optically active (+)-cloprostenol, it exhibits enhanced membrane permeability compared to its parent acid. In veterinary medicine, it has been investigated for its potent luteolytic properties to synchronize estrus and manage reproductive cycles in livestock, demonstrating significantly higher potency than natural PGF2α in terminating pregnancy in animal models. Research has also explored its potential in human medicine for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. It is primarily available as a research chemical and does not have a widely recognized commercial brand name for human therapeutic use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cloprostenol isopropyl ester.